Skip to Main Content

Outcomes

Yale Cancer Center and our partner, Smilow Cancer Hospital, acknowledge the seven American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) evidence-based quality guidelines for breast and colorectal cancers. The latest performance data for breast center is listed below.


Breast Measures Expected Estimated Performance Rates (percentage) Yale Performance 2017 Yale Performance 2018 Yale Performance 2019
Tamoxifen or third generation aromotase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0 or stage IB-III hormone receptor positive breast cancer (Accountability) 90% 92.3 94.9 90.8
Radiation therapy is recommended or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes (Accountability) 90% 84.2* 100 100
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer (Accountability) 90% 93 95.1 94
Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0, or stage IB - III hormone receptor negative breast cancer (Accountability) 90% 90.9 96.5 100

*Total of 3/19 patients received radiation, but occurred more than 1 year after diagnosis (Reasons: (a) 2 patients the decision was to add more chemo s/p neoadjuvant followed by mastectomy due to disease extension; (b) XRT delayed as a patient required an ostomy for an unrelated condition).